Business
Korro Bio Unveils RNA-Editing Therapy KRRO-121, Aiming to Redefine Ammonia Control for Rare Metabolic and Liver Disorders
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.